Minister emphasizes raising awareness about genetic disorders like thalassemia, sickle cell anemia, and hemophilia for timely ...

Treatment options for children with hemophilia A have expanded with the FDA approval of Bayer's Jivi antihemophilic factor ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

BioMarin sees growth from Voxzogo but faces competition and product declines. Market pressures lead to a downgrade from Buy ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.